Semaglutide is a synthetic, lipidated 31-residue GLP-1 receptor agonist peptide supplied as a characterized reference material for in-vitro receptor pharmacology, analytical chemistry, and comparative incretin research. This overview separates molecular identity from clinical marketing language and keeps the material in a Research-Use-Only context.
Molecular identity
Semaglutide is built on a GLP-1-derived peptide backbone with sequence substitutions and a C18 fatty-diacid side chain attached through a linker to a lysine residue. Public compound records describe the material under CAS 910463-68-2, with a reported molecular formula of C₁₈₇H₂₉₁N₄₅O₅₉ and an approximate molecular weight of 4113.6 g/mol. Lot-specific identity should always be checked against the certificate of analysis rather than inferred from a catalog page.
Structural features
The Aib substitution at position 8 and the lipidated side chain are useful topics for structure–activity and peptide-stability studies. In the literature, these features are discussed in relation to protease resistance, receptor engagement, and albumin association. They also make semaglutide a useful comparator when researchers study how backbone changes and conjugation alter the behavior of class-B GPCR peptide ligands.
Research applications
Laboratories may use semaglutide as a defined comparator in GLP-1R binding or signaling assays, cAMP-response experiments, analytical method development, and comparative studies of single-, dual-, and triple-receptor agonists. Results depend on the assay system, receptor expression, concentration range, formulation, and analytical controls; a published observation is not a universal property of every lot or model.
Evidence limits and handling
A reference material is only useful when its identity, purity, storage history, and assay context are documented. Investigators should review the applicable SDS, institutional procedures, lot-specific COA, and primary literature before using the material. This page provides scientific orientation only: Research Use Only, not for human or veterinary use, diagnostic use, or therapeutic use.
Every Semaglutide order includes a sealed, lot-controlled vial, the completed lot documentation, and a handling & storage card. Product-specific handling follows the supplied documentation and institutional SOPs.
Evidence limits and research safety
Research findings can differ by model, assay, purity, formulation, and study design. Published cell, biochemical, and pre-clinical observations do not establish human or veterinary safety, efficacy, dosing, or suitability. Researchers should review the applicable SDS, institutional safety procedures, waste requirements, and lot-specific documentation before handling any reference material.
Related research
Tirzepatide · Retatrutide · AOD9604
Credible sources
- PubChem — Semaglutide
- PubMed — Semaglutide GLP-1 receptor literature
- PubMed — peptide lipidation and incretin analogs